The peak expression of the four genes—MBOAT2, CDA, LPCAT2 and B4GALT5—is where we may use this data to improve the impact of anticancer medications on PACA patients. This evidence concerns the gene B4GALT5 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.